INVESTIGATION ON COLISTIN UTILISATION AT E HOSPITAL

Bảo Kim Nguyễn1, Trung Nghĩa Nguyễn2,, Thị Hà Nguyễn2, Sơn Nhật Bùi1
1 University of Medicine and Pharmacy, VNU
2 E hospital

Main Article Content

Abstract

Objectives: Investigate the characteristics of colistin use (indications, route of administration, dosage regimen, antibiotic combination) in clinical practice at E. Study population and methods: A descriptive cross-sectional study was performed on 61 medical records of patients using colistin from January 2021 to December 2021 at E hospital. Results: The ICU department administered colistin to most patients (83.6%), and pneumonia was the most common indication for colistin in the research (78.7%). Patients who have been prescribed colistin primarily for bacterial targets made up 88.5% of the total, whereas 11.5% of patients were assigned empirically. Colistin is most commonly used in conjunction with other antibiotics (96.8%), particularly carbapenem antibiotics. The loading dosage was administered to the majority of patients, with 13.1% (48/41) failing to do so in accordance with the instructions. The average daily dose of colistin was 4.85 ± 2.16  MIU/day, with a total dose of 72.57 ± 58.98 MIU. Conclusion: Loading dosage has not been employed in all departments. The dosing regimen should be customized depending on the Css target, and there should be more detailed information on how to determine Css at E hospital.

Article Details

References

1. Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther. 2017;15(1):55-65. doi:10.1080/14787210.2017.1251840
2. Stewart S, Robertson C, Pan J, et al. Impact of healthcare-associated infection on length of stay. J Hosp Infect. 2021;114:23-31. doi:10.1016/ j.jhin.2021.02.026
3. Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care Lond Engl. 2019;23(1):383. doi:10.1186/s13054-019-2627-y
4. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39(1):10-39. doi:10.1002/phar.2209
5. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400. doi:10.1016/ S1473-3099 (18)30099-9
6. Huang C, Chen I, Tang T. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. J Clin Med. 2022;11(11):3239. doi:10.3390/ jcm11113239
7. Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2022;2(1):EVIDoa2200131. doi:10.1056/EVIDoa2200131
8. Huê ĐT. Phân tích tình hình sử dụng colistin và đánh giá độc tính thận của colistin điều trị viêm phổi tại khoa Hồi sức tích cực bệnh viện E Hà Nội. Luận văn Thạc sĩ Dược học. Trường Đại học Dược Hà Nội; 2018.
9. Châu ĐTN. Khảo sát tình hình sử dụng kháng sinh colistin tại Bệnh viện Đại học Y Hà Nội. Khóa luận tốt nghiệp Dược sĩ. Trường Đại học Dược Hà Nội; 2018.
10. Hoa PTM. Khảo sát tình hình sử dụng colistin từ tháng 01 đến tháng 06 năm 2020 tại Bệnh viện nhân dân Gia Định. Khóa luận tốt nghiệp Dược sĩ. Trường Đại học Y Dược Tp. Hồ Chí Minh; 2021.